Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSM Hasib SidiqiEZElena ZamagniCTCyrille Touzeau

Discussion

Loading...

Member takes

Overview

Phase 3 CARTITUDE-4 study shows bridging therapy enhances progression-free survival in relapsed multiple myeloma, suggesting new treatment strategies.

Key Points

  • Improved progression-free survival observed after bridging therapy with ciltacabtagene autoleucel infusion, enhancing patient outcomes.
  • Average hazard ratio for progression-free survival was 0.29, while overall survival showed a hazard ratio of 0.55, indicating effectiveness of the treatment.
  • Bridging therapy involved pomalidomide and dexamethasone or daratumumab, followed by a cilta-cel infusion with significant follow-up.
  • Optimal response to bridging therapy may reduce risk of complications and enhance survival rates, highlighting treatment relevance.

Cite This Study

Sidiqi et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7cchttps://doi.org/10.1182/blood-2025-2215
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  2. 2Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma2025 · 4 citations
  3. 3CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  4. 4Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population2025
  5. 5Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality2025 · 7 citations